Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Vitamin C [EPC]
Sus Scrofa Pancreas is a porcine-derived biological agent primarily used in pancreatic enzyme replacement therapy (PERT). It contains essential enzymes like lipase, protease, and amylase to assist in the digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.
Name
Sus Scrofa Pancreas
Raw Name
SUS SCROFA PANCREAS
Category
Vitamin C [EPC]
Drug Count
86
Variant Count
87
Last Verified
February 17, 2026
About Sus Scrofa Pancreas
Sus Scrofa Pancreas is a porcine-derived biological agent primarily used in pancreatic enzyme replacement therapy (PERT). It contains essential enzymes like lipase, protease, and amylase to assist in the digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.
Detailed information about Sus Scrofa Pancreas
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Sus Scrofa Pancreas.
Sus Scrofa Pancreas refers to the medicinal use of pancreatic tissue derived from the domestic pig (Sus scrofa). In clinical pharmacology, this substance is most commonly recognized as the source for Pancrelipase, a concentrated mixture of digestive enzymes including lipase, amylase, and protease. According to the FDA-approved labeling for products derived from Sus Scrofa Pancreas, these agents belong to the therapeutic class of digestive enzymes and are indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI). EPI is a condition where the pancreas does not produce or release enough enzymes to digest food properly, often resulting from conditions such as cystic fibrosis, chronic pancreatitis, or surgical removal of the pancreas.
While Sus Scrofa Pancreas is primarily utilized for its enzymatic content, the raw biological material is a complex matrix. In the context of broader pharmacological classifications, it has been associated with various Established Pharmacologic Classes (EPCs) such as Insulin, Estrogen, and various Amino Acids, as the pancreas is both an exocrine and endocrine organ. However, in modern medicine, standardized porcine pancreatic extracts are strictly regulated to ensure specific enzymatic activity levels (USP units). The FDA first approved standardized porcine pancreatic enzyme products under a new regulatory framework in the late 2000s to ensure consistency across brands like Creon, Zenpep, and Pancreaze.
The primary mechanism of action for Sus Scrofa Pancreas involves the intraduodenal (within the small intestine) replacement of deficient endogenous enzymes. When a patient with pancreatic insufficiency consumes food, the porcine enzymes act as substitutes for the enzymes the patient's own pancreas cannot produce.
At the molecular level, these enzymes must survive the highly acidic environment of the stomach to reach the duodenum, where the pH is higher (more alkaline). Most modern preparations use enteric-coated microspheres to protect the Sus Scrofa Pancreas enzymes from gastric acid degradation, allowing them to release only when they reach the neutral pH of the small intestine.
Unlike traditional systemic drugs, Sus Scrofa Pancreas enzymes are not intended to be absorbed into the bloodstream. Their activity is localized within the gastrointestinal tract.
Healthcare providers typically prescribe Sus Scrofa Pancreas-derived products for the following FDA-approved indications:
Sus Scrofa Pancreas is available in several specialized delivery formats to ensure efficacy:
> Important: Only your healthcare provider can determine if Sus Scrofa Pancreas is right for your specific condition. The choice of brand and dosage form is critical, as these products are not considered bioequivalent by the FDA.
Dosage for Sus Scrofa Pancreas-derived enzymes is highly individualized and is usually based on the patient's weight, the severity of their pancreatic insufficiency, and the fat content of their meals. According to the Cystic Fibrosis Foundation guidelines, dosing typically starts at:
Sus Scrofa Pancreas is frequently used in children, especially those with cystic fibrosis. Dosing is strictly weight-based:
There are no specific dosage adjustments provided by manufacturers for renal impairment, as the enzymes are not systemically absorbed. However, patients with underlying renal issues should be monitored for hyperuricemia (high uric acid levels).
No dosage adjustments are typically required for patients with liver disease, though the underlying cause of pancreatic insufficiency (such as alcoholism) may also affect liver function, requiring overall clinical monitoring.
Clinical trials have not shown significant differences in response between elderly and younger patients. However, healthcare providers usually start at the lower end of the dosing range to assess tolerance.
Proper administration is vital for the effectiveness of Sus Scrofa Pancreas:
If a dose is missed, the patient should skip that dose and take the next dose with their next meal or snack. Do not attempt to "double up" or take enzymes without food, as they will have no substrate to act upon and may cause gastric irritation.
While systemic toxicity is rare, extremely high doses of Sus Scrofa Pancreas can lead to:
In case of suspected massive ingestion, contact a poison control center and seek medical evaluation.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or switch brands without medical guidance, as different products contain different ratios of enzymes.
Most side effects associated with Sus Scrofa Pancreas are gastrointestinal in nature, reflecting the drug's localized action in the digestive tract. Common reports include:
> Warning: Stop taking Sus Scrofa Pancreas and call your doctor immediately if you experience any of these serious symptoms.
With prolonged use, the most significant concern is the maintenance of nutritional balance. While Sus Scrofa Pancreas improves nutrient absorption, patients must be monitored for fat-soluble vitamin (A, D, E, K) deficiencies over time. Additionally, the risk of fibrosing colonopathy remains a long-term consideration for those on high-dose regimens.
Currently, Sus Scrofa Pancreas (Pancrelipase) products do not carry an FDA Black Box Warning. However, they do carry a significant "Warning and Precaution" regarding fibrosing colonopathy, which is treated with the highest level of clinical vigilance. Manufacturers are required to include specific language regarding the risk of viral transmission, as the product is biological and derived from porcine tissues, though no cases of human illness from such transmission have ever been documented.
Report any unusual symptoms or changes in bowel habits to your healthcare provider immediately. Regular follow-ups are necessary to ensure the dosage remains effective and safe.
Sus Scrofa Pancreas is a biological product derived from the pancreatic glands of pigs. Patients must be aware of the origin of the medication, particularly if they have religious or ethical objections to porcine products. Furthermore, the efficacy of the medication is highly dependent on the integrity of the enteric coating; any action that compromises this coating (such as chewing) will render the medication ineffective and potentially harmful to the oral mucosa.
No FDA black box warnings for Sus Scrofa Pancreas. However, the FDA mandates a prominent warning regarding Fibrosing Colonopathy, a serious colonic condition that can lead to bowel obstruction.
Patients taking Sus Scrofa Pancreas require regular clinical monitoring, including:
Sus Scrofa Pancreas is not known to interfere with the ability to drive or operate heavy machinery. It does not have sedative or psychoactive properties.
Alcohol consumption should be avoided or strictly limited. Alcohol can cause or worsen chronic pancreatitis, the very condition for which Sus Scrofa Pancreas is often prescribed. Furthermore, alcohol can interfere with the body's ability to absorb nutrients, counteracting the benefits of the medication.
Do not stop taking Sus Scrofa Pancreas without consulting your doctor. Sudden discontinuation will lead to the return of malabsorption symptoms, including steatorrhea (fatty, foul-smelling stools), abdominal pain, and weight loss. There is no "withdrawal syndrome," but the return of the underlying disease symptoms can be severe.
> Important: Discuss all your medical conditions, including any history of intestinal blockage or gout, with your healthcare provider before starting Sus Scrofa Pancreas.
There are no absolute drug-drug contraindications that require total avoidance of Sus Scrofa Pancreas; however, the following interactions are clinically significant and may require management.
Sus Scrofa Pancreas is not known to significantly interfere with common blood chemistry or hematology lab tests. However, it will directly affect the results of a Fecal Elastase test or 72-hour Fecal Fat test, which are used to diagnose pancreatic insufficiency. Patients may need to temporarily stop enzymes before these specific tests as directed by their physician.
For each major interaction, the management strategy usually involves either adjusting the dose of the enzymes or the interacting medication, or carefully timing the administration to ensure maximum efficacy of both substances.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter digestive aids.
Sus Scrofa Pancreas must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients who are sensitive to other porcine-derived biologicals (such as certain types of insulin or heparin) may have a higher likelihood of sensitivity to Sus Scrofa Pancreas. There is no known cross-sensitivity with bovine (cow) enzymes, although bovine-derived pancreatic enzymes are no longer commonly available in the United States.
> Important: Your healthcare provider will evaluate your complete medical history, including any religious or dietary restrictions regarding porcine products, before prescribing Sus Scrofa Pancreas.
FDA Pregnancy Category C: Animal reproduction studies have not been conducted with Sus Scrofa Pancreas. It is also not known whether these enzymes can cause fetal harm when administered to a pregnant woman. However, since the enzymes are not systemically absorbed, the risk to the fetus is considered theoretically low. The primary concern during pregnancy is maintaining maternal nutrition, as malabsorption can lead to poor fetal outcomes. Healthcare providers will prescribe Sus Scrofa Pancreas during pregnancy only if clearly needed and if the benefits of nutritional maintenance outweigh the unknown risks.
It is not known whether Sus Scrofa Pancreas enzymes are excreted in human milk. However, because these enzymes are proteins and are not absorbed into the mother's systemic circulation, it is highly unlikely that they would be present in breast milk or affect the nursing infant. Breastfeeding is generally considered safe while taking these enzymes, but mothers should monitor their infants for any changes in stooling patterns.
Sus Scrofa Pancreas is a cornerstone of treatment for children with cystic fibrosis. It is approved for use in infants, children, and adolescents. The most significant risk in this population is Fibrosing Colonopathy, which has been reported primarily in children under age 12 taking high doses. Pediatric dosing must be strictly calculated based on weight and fat intake. Parents must be educated on how to administer the capsules (sprinkling on applesauce) without allowing the child to chew the microspheres.
Clinical studies of Sus Scrofa Pancreas did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
In patients with renal impairment, the main concern is the potential for increased uric acid levels. These patients should have their serum uric acid monitored regularly. There is no evidence that the enzymes themselves cause further damage to the kidneys, as they are not systemically absorbed.
No specific studies have been performed in patients with hepatic impairment. However, since the enzymes act locally in the gut and are not metabolized by the liver, hepatic impairment is not expected to affect the drug's pharmacokinetics. Clinical focus should remain on the patient's overall nutritional status.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure both safety and nutritional adequacy.
Sus Scrofa Pancreas acts as an exogenous (external) source of digestive enzymes. The three primary components—lipase, protease, and amylase—catalyze the breakdown of fats, proteins, and starches.
The pharmacodynamic effect of Sus Scrofa Pancreas is measured by the reduction in fecal fat excretion and the improvement in nitrogen absorption. The effect is dose-dependent up to a certain threshold. The onset of action is immediate upon reaching the duodenum, and the duration of effect is limited to the time the food bolus remains in the small intestine. There is no evidence of tolerance development; however, the required dose may increase if the underlying pancreatic disease progresses.
| Parameter | Value |
|---|---|
| Bioavailability | Near 0% (Not systemically absorbed) |
| Protein Binding | N/A (Acts luminally) |
| Half-life | N/A (Degraded by proteolysis in the gut) |
| Tmax | 1-2 hours (Time to reach duodenum) |
| Metabolism | Digested as dietary protein |
| Excretion | Fecal (as inactivated fragments) |
Sus Scrofa Pancreas extract is a yellowish-to-cream colored amorphous powder. It is partially soluble in water and insoluble in alcohol or ether. It is standardized for its enzymatic activity according to the United States Pharmacopeia (USP). The molecular weight varies as it is a mixture of multiple proteins. The enzymes are highly sensitive to pH levels below 5.5 and temperatures above 40°C.
Sus Scrofa Pancreas belongs to the class of Digestive Enzymes. It is specifically categorized as Pancrelipase (USP), which has a higher lipase-to-protease/amylase ratio than the older "Pancreatin" preparations. It is the gold standard for Pancreatic Enzyme Replacement Therapy (PERT).
Common questions about Sus Scrofa Pancreas
Sus Scrofa Pancreas is primarily used as a replacement therapy for people whose bodies do not produce enough digestive enzymes. This condition, known as Exocrine Pancreatic Insufficiency (EPI), is common in patients with cystic fibrosis, chronic pancreatitis, or those who have had pancreatic surgery. By providing lipase, protease, and amylase, the medication helps the body break down and absorb fats, proteins, and sugars from food. Without this treatment, patients may suffer from severe malnutrition, weight loss, and foul-smelling, fatty stools. Your doctor will determine the correct dose based on your specific digestive needs and body weight.
The most common side effects are gastrointestinal, including stomach pain, bloating, gas, and changes in bowel movements such as diarrhea or constipation. These symptoms often occur as your digestive system adjusts to the new enzyme levels. Some patients also report mild nausea or headaches during the start of therapy. If these symptoms become severe or persistent, you should contact your healthcare provider for a dosage adjustment. It is also important to ensure you are taking the medication correctly with food to minimize stomach upset.
It is strongly recommended that you avoid alcohol while taking Sus Scrofa Pancreas. Alcohol is a primary cause of chronic pancreatitis and can lead to further damage of the remaining pancreatic tissue. Additionally, alcohol can irritate the gastrointestinal tract and interfere with the absorption of vital nutrients, which directly counteracts the purpose of the enzyme therapy. Consuming alcohol may also worsen side effects like abdominal pain and nausea. Always discuss your lifestyle habits and alcohol consumption honestly with your healthcare provider.
Sus Scrofa Pancreas is classified as FDA Pregnancy Category C, meaning there is limited data from human studies. However, because the enzymes work locally in the intestines and are not absorbed into the bloodstream, they are generally considered to have a low risk of causing birth defects. The most important factor during pregnancy is ensuring the mother receives adequate nutrition, which requires effective enzyme therapy. If you are pregnant or planning to become pregnant, your doctor will weigh the benefits of nutritional health against any theoretical risks. Never start or stop this medication during pregnancy without medical consultation.
Sus Scrofa Pancreas begins working as soon as it reaches your small intestine and comes into contact with food. This typically happens within 30 to 60 minutes after ingestion, depending on the speed of your digestion. You will not "feel" the medication working in the traditional sense, but you should notice an improvement in your symptoms over several days or weeks. Signs that the medication is working include less frequent and more normal-looking stools, reduced bloating, and gradual weight gain or stabilization. If you do not see improvement in your digestive symptoms within a few weeks, your doctor may need to increase your dose.
You should not stop taking Sus Scrofa Pancreas suddenly unless directed by your doctor. Because this medication replaces enzymes your body cannot make, stopping it will cause your malabsorption symptoms to return almost immediately. This can lead to severe abdominal pain, fatty stools (steatorrhea), and rapid weight loss due to the inability to digest food. While stopping the drug is not life-threatening in the short term, it can lead to serious nutritional deficiencies over time. If you are experiencing side effects that make you want to stop the medication, talk to your doctor about adjusting the dose or switching brands.
If you miss a dose of Sus Scrofa Pancreas, simply skip the missed dose and take your next scheduled dose with your next meal or snack. Do not take the enzymes if you are not eating, as they require food to be effective and can irritate an empty stomach. Never take two doses at once to make up for a missed one. It is helpful to keep a small supply of enzymes with you at all times so you are prepared for unplanned meals or snacks. Consistency is key to maintaining proper nutrition and preventing digestive discomfort.
Sus Scrofa Pancreas can lead to weight gain, but this is usually a positive and intended effect of the treatment. In patients with pancreatic insufficiency, weight loss occurs because the body cannot absorb calories from food. By helping your body digest and absorb nutrients, the enzymes allow you to utilize the calories you consume, leading to healthy weight gain or maintenance. This is not the same as the metabolic weight gain associated with some other medications. If you experience sudden or excessive weight gain that seems unrelated to your improved nutrition, consult your healthcare provider.
Sus Scrofa Pancreas can be taken with most other medications, but some interactions exist. It may reduce the effectiveness of certain diabetes medications like acarbose and can interfere with the absorption of iron supplements. Many patients are prescribed acid-reducing drugs like omeprazole alongside their enzymes to help them work better. It is crucial to provide your doctor with a full list of all prescriptions, over-the-counter drugs, and herbal supplements you use. Your doctor may suggest specific timing for different medications to ensure they all work effectively.
Currently, the FDA does not consider different brands of Sus Scrofa Pancreas (pancrelipase) to be "interchangeable" generics. This means that if your doctor prescribes a specific brand like Creon, the pharmacist cannot automatically switch it to another brand like Zenpep without a new prescription. This is because the manufacturing process for these biological products is complex, and the exact ratio of enzymes can vary between brands. While there are multiple brands available, they are treated as distinct products. Always check your medication to ensure you have received the specific brand your healthcare provider intended.